MAPKs. Smad4 is mutated in 50-80% of PDAC. Mutations of TGF-βRII also occurs (5-10%). 33 In order to decipher the role of TGF-β in carcinogenesis and chemoresistance, we decided to 34 characterize the knocking down of TGF-βRII that is the first actor of TGF-β signalling. We 35 developed pancreatic cancer cell lines stably invalidated for TGF-βRII and studied the impact 36 on biological properties of pancreatic cancer cells both in vitro and in vivo. We show that 37 TGF-βRII silencing alters tumor growth and migration as well as resistance to. silencing also leads to S727 STAT3 and S-63 c-Jun phosphorylation, decrease of MRP3 and 39 increase of MRP4 ABC transporter expression and induction of a partial EMT phenotype. 40 In the future, the better understanding TGF-β signaling pathways and underlying cellular 41 mechanisms in chemoresistance to gemcitabine may bring new therapeutic tools to (Rahib et al., 2014) . The survival curve is extremely short (6 months) 49 and the survival rate at 5 years is very low (3%). This dramatic outcome is related to a lack of 50 therapeutic tools and early diagnostic markers which makes pancreatic cancer the most 51 deadly cancer. At the time of diagnosis, more than 80% of PC are already metastatic or 52 locally advanced and only about 10 to 15% of patients are considered eligible for surgical 53 resection (Vincent et al., 2011) . Remaining patients that do not benefit of surgery will receive 54 palliative chemotherapy and notably gemcitabine, a fluorinated analog of deoxycytidine that 55 is a major chemotherapeutic drug used in firstline in advanced PC. Unfortunately, PC is 56 characterized by an intrinsic and acquired chemoresistance that lead to relapse and death 57 (Kleeff et al., 2016) . Deciphering mechanisms responsible for PC cell resistance to 58 gemcitabine is thus crucial to improve efficacy of the drug and propose more efficient 59 therapies.
60
TGF-β signalling pathway plays a complex role during carcinogenesis. TGF-β initially inhibits 61 epithelial growth whereas it appears to promote the progression of advanced tumors and 62 thus emerged as tumor suppressor pathway in pancreatic cancer (Principe et al., 2014) . Smad4/DPC4 (deleted in pancreatic cancer 4) is mutated in 50-80% of PDAC whereas 69 mutations of TGF-βRII are less common (5-10%) (Kleeff et al., 2016; TCGA-Network., 2017) . 70 We previously showed that TGF-β can regulate gene expression via canonical or alternative 71 signalling pathways (Jonckheere et al., 2004 Figure 1A ).
184
We generated CAPAN-1 and CAPAN-2 stable cell lines in which TGF-βRII was knocked Role of TGF-βRII on PC cells sensitivity to gemcitabine 229 We investigated the effect of TGF-βRII silencing on CAPAN-1 and CAPAN-2 cell sensitivity 230 to gemcitabine. We show that the lack of TGF-βRII induces a significant increase of 231 resistance to gemcitabine treatment in both CAPAN-1 (87-152% increase of survival rate, 232 Figure 3A ) and CAPAN-2 (50-161% increase, Figure 3B ) cell lines compared to NT control 233 cells. All differences were statistically significant. We then carried out SC xenograft of NT or 234 TGF-βRII-KD8 CAPAN-2 cells that were subsequently treated with gemcitabine for 46 days. were scored. We show that STAT3 nuclear H-score in TGF-βRII-KD8 tumors was 258 significantly higher than in NT tumors (*, p=0.0429) ( Figure 5C ). We also observed that 
